Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [68Ga]Ga/[177Lu]Lu–NYM032 for theranostic use in prostate cancer.
Purpose: A novel theranostic radiopharmaceutical targeting prostate-specific membrane antigen (PSMA), [68Ga]Ga/[177Lu]Lu–NYM032, was developed and its diagnostic and therapeutic potential in the treatment of prostate cancer (PCa) was preliminarily evaluated. Methods: The diagnostic efficacy of the P...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 52; no. 5; pp. 1671 - 1685 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Apr2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |